213 related articles for article (PubMed ID: 23093383)
1. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.
Calabrese F; Luoni A; Guidotti G; Racagni G; Fumagalli F; Riva MA
Psychopharmacology (Berl); 2013 Mar; 226(1):101-12. PubMed ID: 23093383
[TBL] [Abstract][Full Text] [Related]
2. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress.
Fumagalli F; Calabrese F; Luoni A; Bolis F; Racagni G; Riva MA
Int J Neuropsychopharmacol; 2012 Mar; 15(2):235-46. PubMed ID: 21349227
[TBL] [Abstract][Full Text] [Related]
3. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.
Luoni A; Hulsken S; Cazzaniga G; Racagni G; Homberg JR; Riva MA
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1319-30. PubMed ID: 23164505
[TBL] [Abstract][Full Text] [Related]
4. Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment.
Luoni A; Rocha FF; Riva MA
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():94-101. PubMed ID: 24361635
[TBL] [Abstract][Full Text] [Related]
5. Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
Yasui-Furukori N
Drug Des Devel Ther; 2012; 6():107-15. PubMed ID: 22675261
[TBL] [Abstract][Full Text] [Related]
6. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence.
Luoni A; Berry A; Calabrese F; Capoccia S; Bellisario V; Gass P; Cirulli F; Riva MA
Eur Neuropsychopharmacol; 2014 Jun; 24(6):986-95. PubMed ID: 24440552
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Loebel A; Cucchiaro J; Silva R; Kroger H; Sarma K; Xu J; Calabrese JR
Am J Psychiatry; 2014 Feb; 171(2):169-77. PubMed ID: 24170221
[TBL] [Abstract][Full Text] [Related]
8. Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation.
Luoni A; Richetto J; Longo L; Riva MA
Eur Neuropsychopharmacol; 2017 Feb; 27(2):170-179. PubMed ID: 27939135
[TBL] [Abstract][Full Text] [Related]
9. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
Tarazi FI; Riva MA
Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
[TBL] [Abstract][Full Text] [Related]
10. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex.
Luoni A; Macchi F; Papp M; Molteni R; Riva MA
Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522402
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone suppresses rapid eye movement sleep and improves sleep quality in rats.
Murai T; Nakamichi K; Shimizu I; Ikeda K
J Pharmacol Sci; 2014; 126(2):164-7. PubMed ID: 25231559
[TBL] [Abstract][Full Text] [Related]
13. [Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic - lurasidone].
Bieńkowski P; Dudek D; Samochowiec J
Psychiatr Pol; 2015; 49(2):243-53. PubMed ID: 26093589
[TBL] [Abstract][Full Text] [Related]
14. Lurasidone (latuda®): an atypical antipsychotic.
Nolan SF; Roman MW
Issues Ment Health Nurs; 2012 May; 33(5):342-3. PubMed ID: 22545643
[TBL] [Abstract][Full Text] [Related]
15. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L
Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
[TBL] [Abstract][Full Text] [Related]
17. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
Yuen EY; Li X; Wei J; Horiguchi M; Meltzer HY; Yan Z
Mol Pharmacol; 2012 Feb; 81(2):113-9. PubMed ID: 22072817
[TBL] [Abstract][Full Text] [Related]
18. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
Ogasa M; Kimura T; Nakamura M; Guarino J
Psychopharmacology (Berl); 2013 Feb; 225(3):519-30. PubMed ID: 22903391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
